|Bringing Biotechnology to You
CHORI Holds BayBio Technology Showcase
CHORI has been a member of the BayBio Institute network since 2007, and in February of this year welcomed over 80 BayBio members to an evening showcase of CHORI’s ground-breaking research and biotechnology developments. CHORI principal investigators presented posters summarizing the research being performed in each of CHORI’s research centers, as well as providing informal introductions to the research and laboratory tours.
“We had a very successful evening, with all the different research centers at CHORI represented and wonderful maps showing where we do research all over the world and in which different countries,” says Suzanne Haendel, who manages CHORI’s Technology Transfer Office.
The BayBio Institute is a non-profit organization that provides the life science community with an invaluable networking resource, connecting all the different players involved in the biotechnology industry with one another, from lawyers to government agencies to scientists.
"CHORI joined the BayBio network in order to have a more visible presence in the biotech community. We are one of the most active research organizations in the area, along with the University of California at San Francisco and Berkeley, yet hardly anyone knows what we are about," says Ms. Haendel.
In fact, with its emphasis on translational research that focuses on bringing the innovation of the lab directly to clinical treatment, CHORI is a nexus for biotechnological advances and has already dozens and dozens of different technologies available, ranging from therapeutics and diagnostics to research reagents and devices. While many of them are in early-stage development, some of them are closer to market, such as the new technique for harvesting stem cells from placenta."As an outgrowth of our sibling donor cord blood program , we've recently identified a way to cryopreserve stem and progenitor cells in whole placenta for use in cellular therapy. This means that we now have a source of cells for cellular therapy in an amount large enough to treat adults, which has been a potential limitation of the cord-blood derived cells," Ms. Haendel explains.
"We want the business and industry community to start to think about CHORI when they think about collaborative research opportunities."
Please visit check out the Technology Transfer Office website for more information about the different biotechnology opportunities available through CHORI.
Tuesday, May 17, 2011 8:19 AM